Madrigal Pharmaceuticals, Inc.
A maker of Rezdiffra, the first FDA-approved drug for MASH, a fatty-liver disease that can lead to serious liver damage. Founded in 2011 by Dr. Rebecca Taub to develop a thyroid-hormone molecule she had rediscovered, the company took its name from the madrigal, a Renaissance choral song, as a nod to restoring harmony to the liver. Fun quirk: it's unrelated to the fictional Madrigal Electromotive from Breaking Bad.
Granted 6.96M · Bought 22.26M · Sold 15.38M
Granted 55.4K · Bought 152.2K
Sold 280.0K
Bought 20.0K
Bought 20.0K
Granted 17.1K · Bought 590.4K
Granted 1.29M · Bought 1.23M · Sold 1.63M
Sold 1.23M
Granted 251.7K · Sold 269.7K
Granted 543.9K · Bought 8.0K · Sold 429.4K
Granted 207.7K · Bought 310.0K
Granted 5.99M · Bought 2.0K · Sold 1.28M
Granted 190.3K · Sold 28.5K
Granted 342.9K
Granted 34.4K · Bought 13.3K
Granted 133.2K · Sold 10.1K
Granted 14.8K · Bought 19.0K · Sold 5.2K
Granted 33.6K · Sold 4.0K
Granted 49.7K · Sold 24.6K
Granted 25.7K
Bought 300
Granted 7.9K · Sold 4.6K
Granted 71.0K · Bought 9.1K · Sold 57.7K
Granted 19.8K
Granted 48.4K · Sold 29.8K
Granted 17.9K
Granted 9.7K · Sold 12.5K
Granted 25.0K · Sold 5.9K
Granted 45.0K · Sold 30.0K
Granted 15.1K · Bought 10.0K · Sold 45.1K
Granted 13.2K · Sold 9.6K
Granted 18.8K · Sold 6.2K
Granted 12.4K · Sold 3.0K
Granted 45.0K · Sold 38.6K
Granted 11.9K · Sold 1.9K
Granted 81.7K · Sold 79.1K
Granted 4.8K
Granted 51.0K · Sold 48.0K
Granted 2.4K
Granted 1.6K
Granted 1.4K
Granted 30.0K · Sold 30.0K
Granted 25.0K
Granted 75.0K
Granted 500.0K
Bought 200
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Kovner BruceDirector, 10% owner · 133 transactions | — | 30.14Mas of Dec 2015 | 6.96M | 22.26M | 15.38M |
| Caxton Corp +1 co-filer10% owner · 1 transaction | — | 7.76Mas of Feb 2007 | — | — | — |
| Bahcall Safi RPresident and CEO, Director · 31 transactions | — | 7.07Mas of Feb 2014 | 55.4K | 152.2K | — |
| Bay City Capital LLCDirector, 10% owner · 2 transactions | — | 5.38Mas of Jun 2018 | — | — | 280.0K |
| Chen Lin Huey10% owner · 7 transactions | — | 4.27Mas of Feb 2010 | — | 20.0K | — |
| Chen Lan BoDirector · 16 transactions | — | 4.25Mas of Feb 2012 | — | 20.0K | — |
| Baker Bros. Advisors LP +5 co-filersDirector · 200 transactions | — | 4.09M | 17.1K | 590.4K | — |
| Gollust Keith RDirector · 66 transactions | — | 2.67Mas of Dec 2015 | 1.29M | 1.23M | 1.63M |
| Bay City Capital Fund IV Co Invesment Fund LP +3 co-filers10% owner · 15 transactions | — | 1.51Mas of Dec 2021 | — | — | 1.23M |
| Taub RebeccaDirector · 111 transactions | — | 1.11M | 251.7K | — | 269.7K |
| Friedman Paul ADirector · 127 transactions | — | 855.9K | 543.9K | 8.0K | 429.4K |
| Wilson Robert NDirector · 19 transactions | — | 760.9Kas of Jul 2015 | 207.7K | 310.0K | — |
| Craves Fred BDirector · 63 transactions | — | 753.9Kas of Mar 2025 | 5.99M | 2.0K | 1.28M |
| Sibold William JohnPresident and CEO, Director · 14 transactions | — | 161.8K | 190.3K | — | 28.5K |
| Schor ChenFormer President and CEO, Director · 4 transactions | — | 51.4Kas of Jul 2016 | 342.9K | — | — |
| Reardon William SDirector · 12 transactions | — | 47.1Kas of Jul 2015 | 34.4K | 13.3K | — |
| Schneebaum Marc RChief Financial Officer · 7 transactions | — | 41.7Kas of Jun 2018 | 133.2K | — | 10.1K |
| Vukovic VojoSVP, Chief Medical Officer · 10 transactions | — | 35.2Kas of Jun 2013 | 14.8K | 19.0K | 5.2K |
| Bailey Michael PSr. VP, Chief Comm. Officer · 3 transactions | — | 29.6Kas of Aug 2010 | 33.6K | — | 4.0K |
| Rieder Wendy EFormer SVP, Gen. Counsel · 10 transactions | — | 26.3Kas of Jul 2016 | 49.7K | — | 24.6K |
| Kufe Donald WDirector · 4 transactions | — | 25.7Kas of Jul 2013 | 25.7K | — | — |
| Jacobson Eric WSr. VP, Research and CMO · 1 transaction | — | 25.3Kas of Feb 2007 | — | 300 | — |
| Chadwick Jeremy GSr. VP, Pgm Mgmt and Clin Ops · 2 transactions | — | 23.8Kas of Mar 2010 | 7.9K | — | 4.6K |
| Levy Richard SDirector · 82 transactions | — | 22.5K | 71.0K | 9.1K | 57.7K |
| Howarth Alex G.Chief Financial Officer · 3 transactions | — | 18.7Kas of Jan 2024 | 19.8K | — | — |
| Lynch Brian JosephSVP and General Counsel · 42 transactions | — | 18.2Kas of Jan 2024 | 48.4K | — | 29.8K |
| Morenstein Scott DDirector · 1 transaction | — | 17.9Kas of Jan 2016 | 17.9K | — | — |
| Ehrlich Keith SVP, Fin. and Admin., CFO · 5 transactions | — | 17.6Kas of Mar 2012 | 9.7K | — | 12.5K |
| Singh AmarSr. VP, Chief Business Officer · 3 transactions | — | 15.2Kas of Dec 2013 | 25.0K | — | 5.9K |
| Sukhija RemyChief Commercial Officer · 20 transactions | — | 15.0Kas of Jan 2023 | 45.0K | — | 30.0K |
| Koya KeizoSr. VP, Drug Development · 7 transactions | — | 13.0Kas of Mar 2012 | 15.1K | 10.0K | 45.1K |
| Dier MardiEVP and CFO · 34 transactions | — | 12.8K | 13.2K | — | 9.6K |
| Huntsman CaroleChief Commercial Officer · 29 transactions | — | 12.7K | 18.8K | — | 6.2K |
| Kelley Shannon TGeneral Counsel · 16 transactions | — | 12.1K | 12.4K | — | 3.0K |
| Waltermire Robert E.Senior VP, Chief Pharma Dev. · 44 transactions | — | 10.9Kas of Mar 2025 | 45.0K | — | 38.6K |
| Soergel DavidChief Medical Officer · 4 transactions | — | 10.0K | 11.9K | — | 1.9K |
| Bate KennethDirector · 57 transactions | — | 8.9K | 81.7K | — | 79.1K |
| Folkman JudahDirector · 1 transaction | — | 7.7Kas of Jun 2007 | 4.8K | — | — |
| Daly James MDirector · 28 transactions | — | 3.1K | 51.0K | — | 48.0K |
| Thakkar RitaChief Accounting Officer · 1 transaction | — | 2.4K | 2.4K | — | — |
| Fouse Jacqualyn ADirector · 3 transactions | — | 1.6K | 1.6K | — | — |
| Brennan Daniel J.Director · 2 transactions | — | 1.4K | 1.4K | — | — |
| Milligan David VDirector · 4 transactions | — | 0as of Nov 2018 | 30.0K | — | 30.0K |
| Bernitz Steven BSVP, Corporate Development · 1 transaction | — | 0as of Dec 2013 | 25.0K | — | — |
| Ramachandra SumantPresident, R&D · 1 transaction | — | 0as of Mar 2013 | 75.0K | — | — |
| Whitaker Anne ClemPresident and CEO, Director · 1 transaction | — | 0as of Sep 2014 | 500.0K | — | — |
| Williams Martin DSr. VP, Business Dev., CBO · 2 transactions | — | 0as of Nov 2007 | — | 200 | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: +3.67M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.